- Home
- ADIL vs RNAZ Comparison
ADIL vs RNAZ Comparison
Compare ADIL & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADIL | RNAZ |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 8.5M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ADIL | RNAZ |
|---|---|---|
| Price | $0.30 | $8.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.50 | ★ $280.00 |
| AVG Volume (30 Days) | ★ 350.0K | 9.2K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $6.15 |
| 52 Week High | $1.30 | $468.44 |
Technical Indicators
Market Signals| Indicator | ADIL | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 41.89 | 35.57 |
| Support Level | $0.30 | $8.20 |
| Resistance Level | $0.33 | $9.00 |
| Average True Range (ATR) | 0.02 | 0.43 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 47.05 | 12.18 |
Price Performance
Historical ComparisonAbout ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.